Cortexyme to Present New GAIN Trial Data at AD/PD 2022
March 14 2022 - 7:00AM
Business Wire
New data expands evidence base of role of P.
gingivalis in Alzheimer’s disease
Discussion to include new biomarker results and
correlations between biomarkers and clinical outcomes
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company pioneering upstream therapeutic
approaches to improve the lives of patients diagnosed with
degenerative diseases, announced that the company will participate
at the AD/PD™ 2022 International Conference on Alzheimer’s and
Parkinson’s Diseases, which is a hybrid event taking place March
15-20, 2022 in Barcelona, Spain, as well as virtually. Cortexyme’s
chief medical officer Michael Detke, MD, PhD, will present new GAIN
Trial results and biomarker data examining the role of P.
gingivalis in Alzheimer’s disease and the P. gingivalis-positive
population, in addition to sharing study data that reinforces the
efficacy of the company’s first-in-class gingipain inhibitor in
slowing cognitive decline in Alzheimer’s disease with P.
gingivalis. These new data analyses will be reviewed at AD/PD 2022
and at additional conferences as more data becomes available
throughout 2022.
AD/PD 2022 Abstract Details
Title: Data from the Phase 2/3 GAIN Trial of COR388
(Atuzaginstat) for the Treatment of Mild-Moderate Alzheimer’s
Disease
- Presenter: Michael Detke, MD, PhD, Cortexyme’s chief medical
officer.
- Authors: Michael Detke1, Marwan Sabbagh2, Mark Ryder3, Joanna
Bolger1, Dave Hennings1, Vladimir Skljarevski1, Shirin Kapur1,
Debasish Raha1, Florian Ermini1, Mai Nguyen1, Ursula Haditsch1, Kim
Perry4, Kelly Ritch5, Suzanne Hendrix6, Sam Dickson6, Hatice
Hasturk7, Sarah Horine1, Craig Mallinckrodt1, Leslie Holsinger1,
Casey Lynch1, and Stephen Dominy1.
- Access: Cortexyme’s AD/PD 2022 presentation will take place on
Sunday, March 20, 2022, at 10:50 a.m. CET (5:50 a.m. EDT) and will
be accessible to AD/PD 2022 registered meeting attendees in-person
and on its virtual platform. The company will issue a news release
summarizing highlights of the presentation and post the
presentation to the science section of its corporate website
shortly after the conclusion of the presentation.
1Cortexyme - South San Francisco, CA (USA), 2Barrow Neurological
Institute, Dignity Health/St. Joseph’s Hospital and Medical Center
- Phoenix, AZ (USA), 3UCSF - San Francisco, CA (USA), 4Innovative
Analytics - Portage, MI (USA), 5Datafy Clinical R&D - Portage,
MI (USA), 6Pentara Corporation - Millcreek, UT (USA), 7Forsyth
Institute - Cambridge, MA (USA)
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
degenerative diseases, including Alzheimer’s disease,
periodontitis, and oral potentially malignant disorders, among
others. Cortexyme’s innovative approach targets a specific,
infectious pathogen called P. gingivalis found in the brain of
Alzheimer’s patients and other organs and tied to degeneration and
inflammation in humans and animal models. The company’s causation
evidence for Alzheimer’s disease and the mechanism of its novel
therapeutic has been independently replicated and confirmed by
multiple laboratories around the world, as well as published in
peer-reviewed scientific journals. To learn more about Cortexyme,
visit www.cortexyme.com or follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “outcomes,”
“intends,” “will,” “estimate,” “potential,” “correlations,”
“reinforces” or other similar words. Examples of forward-looking
statements include, among others, the strategic development path
for atuzaginstat; its business plans, internal and external
development of the pipeline, strategy, planned FDA submissions and
clinical trials and timeline, prospects, and milestone
expectations; the timing and success of the company’s clinical
trials and related data, including plans and the ability to
initiate, conduct and/or complete current and additional studies;
the timing of announcements and updates relating to its clinical
trials and related data; the potential therapeutic benefits, safety
and efficacy of the company’s product candidate or library of
compounds; and statements about its ability to obtain, and the
timing relating to, further development of atuzaginstat and other
programs or indications, regulatory submissions and interactions
with regulators, and related response and decisions, and approvals
with respect to the company’s drug product candidate.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict and could cause actual
results to differ materially from what the company expects.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in Cortexyme’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on
March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC
on October 29, 2021, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220314005261/en/
Stacy Roughan Cortexyme, Inc. Vice President, Corporate
Communications & Investor Relations ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024